Summary
Cytarabine has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Multiple Myeloma would be drug repurposing rather than first-in-human development. This does not mean it is approved for Multiple Myeloma. ClinicalTrials.gov lists 8 registered trials linking Cytarabine to Multiple Myeloma: 4 have completed; 4 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 3 (NCT00574080). The largest enrolment is 200 participants (NCT00281879). Registration activity spans 1992 to 2012. No published literature item is linked to Cytarabine and Multiple Myeloma in the OSMF database yet, so the record rests on registry entries alone. Registry entries describe intent to study, not outcomes.
The RepurpOS disease-intelligence file for Multiple Myeloma ranks 50 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Essentially zero; MGUS (precursor) progresses to myeloma in 1%/year; median survival without treatment <1 year once symptomatic.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 40.0 (trials 20.0, literature 0.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 0 recruiting, 0 active / not yet recruiting, 4 completed, 4 other |
| Linked publications | 0 |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | DGIdb |
| Linked via biomarker / target | CCND1 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT00574080 | UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide 2006 | terminated | Phase 3 | 20 |
| NCT00002502 | Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome 1992 | completed | Phase 2 | — |
| NCT00691015 | Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant 2008 | completed | Phase 2 | 48 |
| NCT01008462 | Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia 2010 | completed | Phase 2 | 16 |
| NCT00281879 | Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer 2006 | terminated | Phase 2 | 200 |
| NCT01653418 | Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation 2012 | terminated | Phase 2 | 10 |
| NCT00002818 | High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies 1995 | completed | Phase 1 | 15 |
| NCT00423826 | Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease 2007 | no_longer_available | Not applicable | — |
Published literature
No publication is linked to this pair yet.
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target CCND1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Cytarabine approved for Multiple Myeloma?
Cytarabine has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Multiple Myeloma would be drug repurposing rather than first-in-human development. This does not mean it is approved for Multiple Myeloma. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Cytarabine in clinical trials for Multiple Myeloma?
ClinicalTrials.gov lists 8 registered trials linking Cytarabine to Multiple Myeloma: 4 have completed; 4 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 3 (NCT00574080). The largest enrolment is 200 participants (NCT00281879). Registration activity spans 1992 to 2012.
What does the evidence show for Cytarabine in Multiple Myeloma?
Cytarabine has 4 completed registered trials for Multiple Myeloma but no linked publication, which usually means results are unpublished, pending, or not yet matched to this record. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target CCND1. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-06. Page built 2026-10-07.